-
公开(公告)号：US08072808B2
公开(公告)日：2011-12-06
申请号：US12128184
申请日：2008-05-28
Applicant: Makoto Arita
Inventor： Makoto Arita
CPC classification number: G11C16/10 , G11C16/3454
Abstract: A memory cell array including at least one memory cell, an address storage section containing address information, an address judging circuit for judging whether an input address matches the address information in the address storage section and outputting a result of the judgment, and a write or erase voltage generation circuit for generating a write or erase voltage to be applied to the memory cell are provided. The write or erase voltage generation circuit receives the output result from the address judging circuit and changes a write or erase voltage.
Abstract translation: 包括至少一个存储单元的存储单元阵列，包含地址信息的地址存储部分，用于判断输入地址是否匹配地址存储部分中的地址信息并输出判断结果的地址判断电路，以及写/ 提供用于产生要施加到存储单元的写或擦除电压的擦除电压产生电路。 写或擦除电压产生电路从地址判断电路接收输出结果并改变写或擦除电压。
-
2.发明申请
公开(公告)号：US20090180961A1
公开(公告)日：2009-07-16
申请号：US12045427
申请日：2008-03-10
Applicant: Charles N. Serhan , Makoto Arita
Inventor： Charles N. Serhan , Makoto Arita
CPC classification number: G01N33/5047 , G01N33/5023 , G01N33/5032 , G01N33/5041 , G01N33/505 , G01N33/566 , G01N2333/4703 , G01N2333/715 , G01N2333/726 , G01N2500/04
Abstract: The present invention is directed to methods for the identification and uses of a receptors that interact with anti-inflammatory compounds derived from eicosapentaenoic acid (EPA). The receptors are of the G-protein coupled receptor (GPCR) family, and are useful to screen candidate substances for anti-inflammatory activity, especially substances that are analogs of EPA. Such analogs are termed “resolvins”; and are typically di- and tri-hydroxy EPA analogs. One analog herein denoted Resolvin E1 was identified in humans and prepared by total synthesis. In nanomolar range Resolvin E1 reduces dermal inflammation, peritonitis, dendritic cells (DCs) migration and IL-12 production. Also described herein is a receptor denoted Reso ER1 that interacts with Resolvin E1 to attenuate cytokine induced activation of inflammatory pathways mediated by transcription factor (NF)-kB. Treatment of DCs with small-interfering RNA specific for ResoE1 eliminated the ligand's ability to regulate IL-12. Assays of anti-inflammatory activity based on these discoveries are also described.
Abstract translation: 本发明涉及鉴定和使用与二十碳五烯酸（EPA）衍生的抗炎化合物相互作用的受体的方法。 受体是G蛋白偶联受体（GPCR）家族，可用于筛选候选物质的抗炎活性，特别是类似于EPA的物质。 这样的类似物被称为“溶解素”; 并且通常是二羟基和三羟基EPA类似物。 在人类中鉴定了一种在本文中称为Resolvin E1的类似物，并通过全合成制备。 在纳摩尔范围内，Resolvin E1可减少皮肤炎症，腹膜炎，树突细胞（DCs）迁移和IL-12的产生。 本文还描述了称为Reso ER1的受体，其与Resolvin E1相互作用以减弱由转录因子（NF）-kB介导的炎症途径的细胞因子诱导的活化。 用特异于ResoE1的小干扰RNA处理DC消除了配体调节IL-12的能力。 还描述了基于这些发现的抗炎活性测定。
-
3.发明授权Semiconductor memory device and control method for the semiconductor memory device 有权半导体存储器件及半导体存储器件的控制方法
公开(公告)号：US07388780B2
公开(公告)日：2008-06-17
申请号：US11471475
申请日：2006-06-21
Applicant: Makoto Arita
Inventor： Makoto Arita
IPC: G11C16/04
CPC classification number: G11C16/10 , G11C11/5628 , G11C11/5642 , G11C16/0483
Abstract: A memory cell array for memorizing data with any of 0th through fourth threshold voltages and a flag memory unit for memorizing a flag data showing a chronological sequence relationship between writing operations in which data in first and second pages are respectively written are provided. A controller shifts a state of the memory cell from the 0th state to the 0th or first state in accordance with the data in the first page, and shifts the state of the memory cell to any of the 0th, first, second and third states in accordance with the data in the second page in a “forward” writing operation. The controller shifts the state of the memory cell from the 0th state to the 0th or third state in accordance with the data in the second page, and shifts the state of the memory cell to any of the 0th, first, third and fourth states in accordance with the data in the first page in a “reverse” writing operation. A flag data showing the “reverse” writing operation is then memorized in the flag memory unit.
Abstract translation: 提供了用于存储具有第0至第4阈值电压中的任一个的数据的存储单元阵列和用于存储表示在其中分别写入第一和第二页数据的写入操作之间的时间顺序关系的标志数据的标志存储单元。 控制器根据第一页中的数据将存储单元的状态从第0状态转移到第0状态或第1状态，并将存储单元的状态转移到第0，第1，第2和第3状态中的任一状态 根据第二页中的数据进行“转发”写操作。 控制器根据第二页中的数据将存储单元的状态从第0状态转移到第0或第3状态，并将存储单元的状态转移到第0，第1，第3和第4状态中的任一状态 根据第一页中的数据进行“反向”写入操作。 表示“反转”写入动作的标志数据然后被存储在标志存储器单元中。
-
4.发明申请Semiconductor memory device and control method for the semiconductor memory device 有权半导体存储器件及半导体存储器件的控制方法
公开(公告)号：US20070011512A1
公开(公告)日：2007-01-11
申请号：US11471475
申请日：2006-06-21
Applicant: Makoto Arita
Inventor： Makoto Arita
IPC: G11C29/00
CPC classification number: G11C16/10 , G11C11/5628 , G11C11/5642 , G11C16/0483
Abstract: A memory cell array for memorizing data with any of 0th through fourth threshold voltages and a flag memory unit for memorizing a flag data showing a chronological sequence relationship between writing operations in which data in first and second pages are respectively written are provided. A controller shifts a state of the memory cell from the 0th state to the 0th or first state in accordance with the data in the first page, and shifts the state of the memory cell to any of the 0th, first, second and third states in accordance with the data in the second page in a “forward” writing operation. The controller shifts the state of the memory cell from the 0th state to the 0th or third state in accordance with the data in the second page, and shifts the state of the memory cell to any of the 0th, first, third and fourth states in accordance with the data in the first page in a “reverse” writing operation. A flag data showing the “reverse” writing operation is then memorized in the flag memory unit.
Abstract translation: 提供了用于存储具有第0至第4阈值电压中的任一个的数据的存储单元阵列和用于存储表示在其中分别写入第一和第二页数据的写入操作之间的时间顺序关系的标志数据的标志存储单元。 控制器根据第一页中的数据将存储单元的状态从第0状态转移到第0状态或第1状态，并将存储单元的状态转移到第0，第1，第2和第3状态中的任一状态 根据第二页中的数据进行“转发”写操作。 控制器根据第二页中的数据将存储单元的状态从第0状态转移到第0或第3状态，并将存储单元的状态转移到第0，第1，第3和第4状态中的任一状态 根据第一页中的数据进行“反向”写入操作。 表示“反转”写入动作的标志数据然后被存储在标志存储器单元中。
-
5.发明申请Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs 有权用于二十碳五烯酸类似物的抗炎症受体的鉴定和使用方法
公开(公告)号：US20060024758A1
公开(公告)日：2006-02-02
申请号：US11218281
申请日：2005-09-01
Applicant: Charles Serhan , Makoto Arita
Inventor： Charles Serhan , Makoto Arita
IPC: G01N33/53 , G01N33/567
CPC classification number: G01N33/5047 , G01N33/5023 , G01N33/5032 , G01N33/5041 , G01N33/505 , G01N33/566 , G01N2333/4703 , G01N2333/715 , G01N2333/726 , G01N2500/04
Abstract: The present invention is directed to methods for the identification and uses of a receptors that interact with anti-inflammatory compounds derived from eicosapentaenoic acid (EPA). The receptors are of the G-protein coupled receptor (GPCR) family, and are useful to screen candidate substances for anti-inflammatory activity, especially substances that are analogs of EPA. Such analogs are termed “resolvins”; and are typically di- and tri-hydroxy EPA analogs. One analog herein denoted Resolvin E1 was identified in humans and prepared by total synthesis. In nanomolar range Resolvin E1 reduces dermal inflammation, peritonitis, dendritic cells (DCs) migration and IL-12 production. Also described herein is a receptor denoted Reso ER1 that interacts with Resolvin E1 to attenuate cytokine induced activation of inflammatory pathways mediated by transcription factor (NF)-kB. Treatment of DCs with small-interfering RNA specific for ResoE1 eliminated the ligand's ability to regulate IL-12. Assays of anti-inflammatory activity based on these discoveries are also described.
Abstract translation: 本发明涉及鉴定和使用与二十碳五烯酸（EPA）衍生的抗炎化合物相互作用的受体的方法。 受体是G蛋白偶联受体（GPCR）家族，可用于筛选候选物质的抗炎活性，特别是类似于EPA的物质。 这样的类似物被称为“溶解素”; 并且通常是二羟基和三羟基EPA类似物。 在人类中鉴定了一种在本文中称为Resolvin E1的类似物，并通过全合成制备。 在纳摩尔范围内，Resolvin E1可减少皮肤炎症，腹膜炎，树突细胞（DCs）迁移和IL-12的产生。 本文还描述了称为Reso ER1的受体，其与Resolvin E1相互作用以减弱由转录因子（NF）-kB介导的炎症途径的细胞因子诱导的活化。 用特异于ResoE1的小干扰RNA处理DC消除了配体调节IL-12的能力。 还描述了基于这些发现的抗炎活性测定。
-
公开(公告)号：US08853437B2
公开(公告)日：2014-10-07
申请号：US13202489
申请日：2010-02-19
Applicant: Makoto Arita , Hiroyuki Arai , Yousuke Isobe , Ryo Taguchi
Inventor： Makoto Arita , Hiroyuki Arai , Yousuke Isobe , Ryo Taguchi
IPC: C07C59/42 , C07C233/09 , A61K31/16 , A61K31/11 , C07C291/00 , C12P7/64
CPC classification number: C07C59/42 , C12P7/6427 , C12P7/6436
Abstract: An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.
Abstract translation: 本发明的目的是提供一种具有克服常规类固醇剂和NSAID缺陷的新颖结构的化合物。 已经发现，二十碳五烯酸和二十二碳六烯酸的二羟基体通常不是已知的（11,18-二羟基二十碳五烯酸（11,18-diHEPE），17,18-二羟基二十碳五烯酸（17,18-diHEPE ）等）具有抑制嗜中性粒细胞的活性，从而解决了对象。 本发明意外地显着地抑制了在急性炎症中发现的组织和嗜中性粒细胞的活化。 本发明的化合物是通常未知的化合物。 因此，提供了作为新治疗剂的效用。
-
公开(公告)号：US09238634B2
公开(公告)日：2016-01-19
申请号：US13817079
申请日：2011-08-04
Applicant: Makoto Arita , Hiroyuki Arai , Yosuke Isobe , Tadafumi Kubota
Inventor： Makoto Arita , Hiroyuki Arai , Yosuke Isobe , Tadafumi Kubota
IPC: A01N43/20 , A01N43/24 , A61K31/335 , C07D303/14 , C07D303/38 , C12P7/64 , C12P17/02 , G01N30/34 , G01N30/72 , G01N30/88
CPC classification number: C07D303/14 , C07D303/38 , C12P7/6427 , C12P17/02 , C12Y113/11 , G01N30/34 , G01N30/7233 , G01N2030/884
Abstract: The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations.
Abstract translation: 目的是提供一种可以克服常规类固醇药物和NSAID的缺点的化合物。 发现由式[化学式1]，[化学式5]等独立地表示的二十碳五烯酸，二十二碳六烯酸和二十二碳五烯酸的特定环氧单羟基形式对中性粒细胞具有抑制活性。 这种化合物可以抑制嗜中性粒细胞侵袭到组织中，并且可以在急性炎症中观察到嗜中性粒细胞的活化。
-
8.发明申请
公开(公告)号：US20130274327A1
公开(公告)日：2013-10-17
申请号：US13817079
申请日：2011-08-04
Applicant: Makoto Arita , Hiroyuki Arai , Yosuke Isobe , Tadafumi Kubota
Inventor： Makoto Arita , Hiroyuki Arai , Yosuke Isobe , Tadafumi Kubota
IPC: C07D303/14
CPC classification number: C07D303/14 , C07D303/38 , C12P7/6427 , C12P17/02 , C12Y113/11 , G01N30/34 , G01N30/7233 , G01N2030/884
Abstract: The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations.
Abstract translation: 目的是提供一种可以克服常规类固醇药物和NSAID的缺点的化合物。 发现由式[化学式1]，[化学式5]等独立地表示的二十碳五烯酸，二十二碳六烯酸和二十二碳五烯酸的特定环氧单羟基形式对中性粒细胞具有抑制活性。 这种化合物可以抑制嗜中性粒细胞侵袭到组织中，并且可以在急性炎症中观察到嗜中性粒细胞的活化。
-
公开(公告)号：US20070118719A1
公开(公告)日：2007-05-24
申请号：US11595896
申请日：2006-11-13
Applicant: Takao Ozeki , Makoto Arita , Kunisato Yamaoka , Shunichi Iwanari
Inventor： Takao Ozeki , Makoto Arita , Kunisato Yamaoka , Shunichi Iwanari
IPC: G06F12/00
CPC classification number: G06F12/1009 , G06F12/1408 , G06F2212/2022
Abstract: There is provided a method for controlling a semiconductor memory which includes a memory cell array including a plurality of multivalued memory cells where, in each of the memory cells, a first write operation allows storage of data in a first page address and a second write operation allows storage of data in a second page address, the method comprising an address conversion table processing step and an address scramble step. At the address conversion table processing step, an address conversion table for address conversion is generated by, in each of the plurality of multivalued memory cells, allocating addresses in which writing is to be performed to addresses such that data is written in a second page address after writing of data in a first page address. At the address scramble step, address conversion is performed on an input address according to the address conversion table.
Abstract translation: 提供了一种用于控制半导体存储器的方法，其包括具有多个多值存储器单元的存储单元阵列，其中，在每个存储器单元中，第一写入操作允许将数据存储在第一页地址和第二写入操作 允许将数据存储在第二页地址中，该方法包括地址转换表处理步骤和地址加扰步骤。 在地址转换表处理步骤中，通过在多个多值存储器单元中的每一个中生成用于地址转换的地址转换表，分配要执行写入的地址以使得将数据写入第二页地址 在第一页地址写入数据之后。 在地址加扰步骤中，根据地址转换表对输入地址执行地址转换。
-
公开(公告)号：US20120059061A1
公开(公告)日：2012-03-08
申请号：US13202489
申请日：2010-02-19
Applicant: Makoto Arita , Hiroyuki Arai , Yousuke Isobe , Ryo Taguchi
Inventor： Makoto Arita , Hiroyuki Arai , Yousuke Isobe , Ryo Taguchi
CPC classification number: C07C59/42 , C12P7/6427 , C12P7/6436
Abstract: An object of the present invention is to provide a compound having a novel structure for overcoming the defects of conventional steroid agents and NSAIDs. It is found that the particular dihydroxy bodies of eicosapentaenoic acid and docosahexaenoic acid, which have not conventionally been known (11,18-dihydroxy eicosapentaenoic acid (11,18-diHEPE), 17,18-dihydroxy eicosapentaenoic acid (17,18-diHEPE) etc.), have activity of inhibiting neutrophil, thereby solving the object. The present invention unexpectedly remarkably inhibits infiltration into a tissue of, and activation of neutrophil found out at acute inflammation. The compound of the present invention is a compound which has not conventionally been known. Therefore, utility as a new therapeutic is provided.
Abstract translation: 本发明的目的是提供一种具有克服常规类固醇剂和NSAID缺陷的新颖结构的化合物。 已经发现，二十碳五烯酸和二十二碳六烯酸的二羟基体通常不是已知的（11,18-二羟基二十碳五烯酸（11,18-diHEPE），17,18-二羟基二十碳五烯酸（17,18-diHEPE ）等）具有抑制嗜中性粒细胞的活性，从而解决了对象。 本发明意外地显着地抑制了在急性炎症中发现的组织和嗜中性粒细胞的活化。 本发明的化合物是通常未知的化合物。 因此，提供了作为新治疗剂的效用。
